Frequent loss of heterozygosity on chromosomes 3p and 17p without VHL or p53 mutations suggests involvement of unidentified tumor suppressor genes in follicular thyroid carcinoma

被引:89
作者
Grebe, SKG
McIver, B
Hay, ID
Wu, PSC
Maciel, LMZ
Drabkin, HA
Goellner, JR
Grant, CS
Jenkins, RB
Eberhardt, NL
机构
[1] MAYO CLIN & MAYO FDN, DEPT MED, ROCHESTER, MN 55905 USA
[2] MAYO CLIN & MAYO FDN, DEPT BIOCHEM, ROCHESTER, MN 55905 USA
[3] MAYO CLIN & MAYO FDN, DEPT BIOL MOL, ROCHESTER, MN 55905 USA
[4] MAYO CLIN & MAYO FDN, DEPT SURG, ROCHESTER, MN 55905 USA
[5] UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA
[6] UNIV SAO PAULO, DEPT INTERNAL MED, BR-14049 RIBEIRAO PRETO, SP, BRAZIL
[7] UNIV COLORADO, CTR CANC, DIV MED ONCOL, DENVER, CO 80262 USA
关键词
D O I
10.1210/jc.82.11.3684
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Follicular thyroid carcinoma (FTC) exhibits frequent loss of heterozygosity (LOH) on chromosomes 10q and 3p, suggesting involvement of tumor suppressor genes. We screened 14 FTC (10 Hurthle cell carcinomas and 4 nonoxyphilic FTC), 14 papillary thyroid carcinomas, and 7 follicular adenomas for LOH on chromosome arms 1p, 3p, 3q, 10p, 10q, 11p, 11q, 13q, 17p, and 17q. LOH was more frequent in FTC than in follicular adenoma or papillary thyroid carcinoma. In FTC, rates of LOH on 3p (86%), 17p (72%), and 10q (57%) were higher than the average rate of LOH (33%; P < 0.05). Most frequently involved were 3p21-25 and 17p13.1-13.3, the sites for the VHL (3p25-26) and p53 (17p13.1) tumor suppressors. We, therefore, characterized these genes by dideoxy fingerprinting and DNA sequencing. Two FTC had mutations in p53, but only 1 of these exhibited LOH at 17p. No VHL gene mutations were found. Thus, neither p53 nor VHL genes play a significant role in the pathogenesis of differentiated thyroid cancer. LOR on 17p, but not on 3p or 10q, was correlated with mortality. Accordingly, 3p and 10q LOH may represent early, and 17p LOH late, events in FTC development. The data suggest the presence of novel tumor suppressor genes on chromosomes 3p and 17p that may be important in the pathogenesis of FTC.
引用
收藏
页码:3684 / 3691
页数:8
相关论文
共 34 条
  • [1] BLASZYK H, 1995, BIOTECHNIQUES, V18, P256
  • [2] BONDESON L, 1989, CANCER, V64, P680, DOI 10.1002/1097-0142(19890801)64:3<680::AID-CNCR2820640319>3.0.CO
  • [3] 2-I
  • [4] BRAUCH H, 1994, WORLD J UROL, V12, P162
  • [5] LOCALIZATION OF THE MEN1 GENE TO A SMALL REGION WITHIN CHROMOSOME 11Q13 BY DELETION MAPPING IN TUMORS
    BYSTROM, C
    LARSSON, C
    BLOMBERG, C
    SANDELIN, K
    FALKMER, U
    SKOGSEID, B
    OBERG, K
    WERNER, S
    NORDENSKJOLD, M
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (05) : 1968 - 1972
  • [6] IMPLICATIONS OF THE P53 TUMOR-SUPPRESSOR GENE IN CLINICAL ONCOLOGY
    CHANG, FJ
    SYRJANEN, S
    SYRJANEN, K
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (04) : 1009 - 1022
  • [7] CHUNG DC, 1996, P 10 INT C END, P961
  • [8] COGEN PH, 1992, AM J HUM GENET, V50, P584
  • [9] CORNELIS RS, 1994, CANCER RES, V54, P4200
  • [10] HIGH PREVALENCE OF MUTATIONS OF THE P53 GENE IN POORLY DIFFERENTIATED HUMAN THYROID CARCINOMAS
    FAGIN, JA
    MATSUO, K
    KARMAKAR, A
    CHEN, DL
    TANG, SH
    KOEFFLER, HP
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (01) : 179 - 184